Keyphrases
Voltage-gated Sodium Channel
100%
Analgesic Effect
100%
Sodium Channel Blockade
100%
Orphenadrine
100%
Sodium Channel
37%
Nav1.5
25%
Nav1.1
25%
Whole Cell
25%
NaV1.8 Channels
25%
Nav1.9 Channel
25%
Musculoskeletal Disorders
12%
Site-directed mutagenesis
12%
Adverse Reactions
12%
Clinically Significant
12%
Skeletal muscle
12%
Multi-target
12%
Parkinson's Disease
12%
N-methyl-D-aspartate Receptor (NMDAR)
12%
Patch Clamp
12%
Mechanism of Action
12%
Clinical Efficacy
12%
Voltage Dependence
12%
DRG Neurons
12%
Primary Culture
12%
HEK293 Cells
12%
Frequency Dependence
12%
Sodium Current
12%
Nav1.7
12%
Analgesic
12%
Local Anesthetics
12%
Sodium Channel Blocker
12%
Pain Sensation
12%
Chronic Pain Syndrome
12%
Mexiletine
12%
Flecainide
12%
Nav1.4
12%
Nav1.7 Channel
12%
Analgesic Compounds
12%
Tetrodotoxin-resistant Sodium Currents
12%
Pharmacology, Toxicology and Pharmaceutical Science
Orphenadrine
100%
Analgesic Agent
100%
Voltage Gated Sodium Channel
100%
Sodium Channel
50%
Sodium Channel Nav1.9
25%
Sodium Channel Nav1.8
25%
Toxic Injury
12%
Tetrodotoxin
12%
Local Anesthetic Agent
12%
Site-Directed Mutagenesis
12%
Primary Culture
12%
Sodium Channel Blocking Agent
12%
Receptor
12%
Chronic Pain
12%
Adverse Event
12%
Musculoskeletal Disease
12%
N Methyl Dextro Aspartic Acid Receptor
12%
Muscarinic Receptor
12%
Sodium Channel Nav1.7
12%
Parkinson's Disease
12%
Mexiletine
12%
Flecainide
12%
Neuroscience
Voltage Gated Sodium Channel
100%
Orphenadrine
100%
Sodium Channel
50%
Nav1.1
25%
Sodium Current
25%
Nav1.5
25%
Sodium Channel Nav1.9
25%
Sodium Channel Nav1.8
25%
Sensory Neuron
12%
Treatment of Parkinson's Disease
12%
Tetrodotoxin
12%
Mexiletine
12%
Primary Culture
12%
Flecainide
12%
NMDA Receptor
12%
Muscarinic Acetylcholine Receptor
12%
Skeletal Muscle
12%
Sodium Channel Nav1.7
12%
Sodium Channel Blocker
12%
Chronic Pain Syndrome
12%
Nav1.4
12%
Patch Clamp
12%
Nociception
12%
Receptor
12%
Site-Directed Mutagenesis
12%